체외 독성 시험 시장 : 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The In Vitro Toxicology Testing Market size is estimated at USD 13.06 billion in 2025, and is expected to reach USD 21.69 billion by 2030, at a CAGR of 10.67% during the forecast period (2025-2030).

This pace underscores the sector's central role in safeguarding human health across pharmaceuticals, cosmetics, and chemicals while meeting global regulations that discourage animal testing. Tighter safety mandates, the FDA's New Alternative Methods program, and Europe's roadmap to phase out animal models are spurring demand. Parallel advances in 3D cell culture, organ-on-chip systems, and AI-enabled analytics are raising predictive accuracy, trimming R&D costs, and opening new revenue streams for contract research organizations. Investor interest remains strong as the technology shift promises earlier toxicity detection, fewer late-stage failures, and faster time-to-market for innovative therapeutics.

Global In Vitro Toxicology Testing Market Trends and Insights

Opposition to the Usage of Animals in Pre-clinical Research

Ethical pressure and regulatory bans continue to displace animal studies. The Society of Toxicology notes that Europe's strict cosmetics directive and the FDA Modernization Act 2.0 have legitimized non-animal approaches. As companies align with these rules, demand for validated in vitro assays accelerates. Multinational firms now embed alternative methods into global submission dossiers, creating unified workflows across regions. The trend also catalyzes public-private partnerships that share reference data to speed assay validation. Rising social awareness further encourages investors to favor firms offering cruelty-free testing services.

Significant Advancements In-vitro Toxicology Assays

Breakthroughs in 3D organoids, microfluidics, and single-cell analytics deliver richer human-relevant data. Microfluidic lung-on-chip models now evaluate particulate toxicity with higher throughput than classical air-liquid interface tests. Combined with real-time imaging and AI, scientists can capture subtle phenotypic changes hours after exposure. These tools support regulatory decision-making for complex endpoints such as developmental neurotoxicity, where rodent models often fall short. As protocols mature, CROs integrate assay bundles to provide full mechanistic insights, boosting their revenue per project.

Incapability of In-vitro Models to Determine Autoimmunity and Immunostimulation

Even sophisticated 3D tissues lack full immune complexity. AZoLifeSciences underscores that organoids without vascular and lymphoid components struggle to predict cytokine storms. Biologics developers therefore still complement assays with in vivo studies. Emerging multi-organ-on-chip systems show promise, but reproducibility and regulatory validation remain ongoing challenges, delaying widespread adoption.

Other drivers and restraints analyzed in the detailed report include:

1. Increasing Awareness Regarding Drug Product Safety
2. Rising Demand for Personalized Medicine
3. Stringent Regulatory Framework for the In-vitro Tests

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Cell culture retained the largest share at 43.91% of in vitro toxicology testing market in 2024, benefiting from mature protocols and broad user familiarity. The segment's strength lies in its versatility across exploratory screens, potency assays, and regulatory submissions. The in vitro toxicology testing market size for Cell Culture applications is projected to remain above USD 8 billion by 2030 as enhancements such as CRISPR-edited lines and AI-assisted imaging unlock new mechanistic insights. Emerging 3D constructs further emulate human organs, reducing false negatives often seen with two-dimensional monolayers.

OMICS approaches, spanning transcriptomics, proteomics, and metabolomics, recorded the fastest CAGR at 13.88% to 2030. Rapid declines in sequencing costs and advances in single-cell analytics broaden adoption among pharma, biotech, and academia. The integration of multi-omics layers offers systems-level toxicological signatures that complement phenotypic screens, positioning OMICS as a cornerstone of next-generation safety pipelines. As datasets grow, machine-learning models trained on OMICS fingerprints refine structure-activity relationships and predict idiosyncratic toxicities earlier in drug discovery.

Cellular assays commanded 36.28% of the in vitro toxicology testing market share in 2024. Fluorescent reporter systems and automated microscopy supply quantitative data on apoptosis, oxidative stress, and DNA damage, underpinning regulatory-grade submissions. Concurrently, in-silico techniques are projected to generate the highest revenue increment, propelled by cloud-based machine-learning platforms that screen virtual libraries at minimal incremental cost.

The in vitro toxicology testing market size for in-silico tools is growing with CAGR 13.88% between 2025 and 2030, driven by pharmaceutical portfolio rationalization and regulatory acceptance of data-rich computational evidence. Biochemical assays and ex-vivo preparations continue to address pathway-specific questions and serve as bridging tools for complex endpoints where predictive models lack validation.

The in Vitro Toxicology Testing Market Report is Segmented by Technology (Cell Culture, High Throughput, and More), Method (Cellular Assay, Biochemical Assay, and More), Application (Systemic Toxicology, and More), End User (Pharmaceutical Industry, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America led the in vitro toxicology testing market with 47.75% revenue in 2024, supported by FDA funding for alternative methods and high R&D spend per capita. The in vitro toxicology testing market size in the United States is driven by rapid adoption of AI-guided high-throughput platforms and a favorable reimbursement environment for advanced diagnostics. Regulatory clarity around laboratory-developed tests, although stringent, signals official endorsement of validated in vitro technologies.

Asia-Pacific is the fastest-growing region, forecast at 12.58% CAGR from 2025 to 2030. Multinational firms establish regional innovation hubs to tap the vast patient base and cost-effective talent pool. These factors collectively elevate local demand for predictive safety solutions that meet global regulatory criteria.

Europe holds a firm second place, bolstered by stringent animal-test bans and progressive chemical-safety directives. The European Commission's November 2024 roadmap to eliminate animal studies propels early adoption of organ-on-chip and multi-omics assays. Regional consortia standardize validation pathways, offering companies smoother submission routes. Meanwhile, emerging markets in South America and the Middle East & Africa witness steady uptake as healthcare infrastructure and pharmacovigilance frameworks mature, presenting long-term growth prospects for test kit suppliers and service providers.

1. Charles River
2. Thermo Fisher Scientific
3. Eurofins
4. SGS
5. Merck
6. Agilent Technologies
7. Abbott Laboratories
8. Bio-Rad Laboratories
9. Danaher
10. GE HealthCare Technologies Inc.
11. Intertek Group
12. Quest Diagnostics
13. Catalent
14. Evotec
15. WuXi AppTec Co. Ltd.
16. Cyprotex Ltd.
17. Promega
18. MB Research Laboratories
19. Gentronix Ltd.
20. BioIVT

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Opposition to the Usage of Animals in Pre-clinical Research
  • 4.2.2 Significant Advancements In-vitro Toxicology Assays
  • 4.2.3 Increasing Awareness Regarding Drug Product Safety
  • 4.2.4 Rising Demand for Personalized Medicine
  • 4.2.5 Growth in High-Throughput Screening Technologies
  • 4.2.6 Regulatory Push for Animal-Free Testing
• 4.3 Market Restraints
  • 4.3.1 Incapability of In-vitro Models to Determine Autoimmunity and Immunostimulation
  • 4.3.2 Stringent Regulatory Framework for the In-vitro Tests
  • 4.3.3 Limited Predictive Accuracy for Complex Systemic Toxicities
  • 4.3.4 Data Management & Integration Challenges
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitutes
  • 4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Technology
  • 5.1.1 Cell Culture
  • 5.1.2 High Throughput
  • 5.1.3 Molecular Imaging
  • 5.1.4 OMICS
  • 5.1.5 3D Cell Culture & Organoids
• 5.2 By Method
  • 5.2.1 Cellular Assay
  • 5.2.2 Biochemical Assay
  • 5.2.3 In-Silico
  • 5.2.4 Ex-Vivo
• 5.3 By Application
  • 5.3.1 Systemic Toxicology
  • 5.3.2 Dermal Toxicity
  • 5.3.3 Endocrine Disruption
  • 5.3.4 Ocular Toxicity
  • 5.3.5 Other Applications
• 5.4 By End User
  • 5.4.1 Pharmaceutical Industry
  • 5.4.2 Biotechnology & CROs
  • 5.4.3 Diagnostics
  • 5.4.4 Academic & Research Institutes
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Charles River Laboratories International Inc.
  • 6.3.2 Thermo Fisher Scientific Inc.
  • 6.3.3 Eurofins Scientific SE
  • 6.3.4 SGS SA
  • 6.3.5 Merck KGaA
  • 6.3.6 Agilent Technologies Inc.
  • 6.3.7 Abbott Laboratories
  • 6.3.8 Bio-Rad Laboratories Inc.
  • 6.3.9 Danaher Corporation
  • 6.3.10 GE HealthCare Technologies Inc.
  • 6.3.11 Intertek Group plc
  • 6.3.12 Quest Diagnostics Inc.
  • 6.3.13 Catalent Inc.
  • 6.3.14 Evotec SE
  • 6.3.15 WuXi AppTec Co. Ltd.
  • 6.3.16 Cyprotex Ltd.
  • 6.3.17 Promega Corporation
  • 6.3.18 MB Research Laboratories
  • 6.3.19 Gentronix Ltd.
  • 6.3.20 BioIVT LLC

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment